Name: BHQ
Brand: Selleck Chemicals
SKU: S3628
Availability: InStock
Rating: 5 (2 reviews)

Jump to

Quality Control

Batch: S362801 Ethanol]40 mg/mL]false]DMSO]10 mg/mL]false]Water]Insoluble]false Purity: 99.52%

Cited in Nature Medicine for its top-tier quality
COA
HPLC
SDS
Datasheet

99.52

Related Targets	CFTR CRM1 CD markers AChR Calcium Channel Sodium Channel Potassium Channel GABA Receptor TRP Channel ATPase
Other ADC Cytotoxin Inhibitors	SN-38 Triptolide (+)-Bicuculline Rutin Artemisinin Pinocembrin Harmine hydrochloride Psoralen Lappaconite HBr Luteoloside

Solubility

In vitro
Batch:

Ethanol : 40 mg/mL

DMSO : 10 mg/mL (44.98 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%Ethanol 1 30%PEG300 2 65%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.000mg/ml (9.00mM)	Taking the 1 mL working solution as an example, add 50 μL of 40 mg/ml clarified Ethanol stock solution to 300 μL of PEG300, mix evenly to clarify it; then continue to add 650 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	222.32	Formula	C₁₄H₂₂O₂	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	88-58-4	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	2,5-di-t-butyl-1,4-benzohydroquinone			Smiles	CC(C)(C)C1=CC(=C(C=C1O)C(C)(C)C)O

Mechanism of Action

Targets/IC₅₀/Ki	SERCA 66.7 μM
In vitro	2,5-Di-t-butyl-1,4-benzohydroquinone (BHQ) has been described as a rather selective sarco-endoplasmic reticulum Ca2+-ATPase (SERCA) inhibitor. However, this compound is not very specific, as it hits other sites of action besides SERCA. It is shown, in fact, to reduce passive Ca2+ leakage from internal stores of permeabilized A7r5 vascular smooth muscle cells and to inhibit plasma membrane Ca2+ influx in parotid acinar cells, rat thymic lymphocytes, and GH3 pituitary cells. This chemical affects both endothelial and smooth muscle functions in rat aorta rings in vitro. It induces endothelium-dependent relaxation by stimulating the NO synthase pathway, via activation of Ca2+ influx through Ni2+-sensitive Ca2+ channels in the endothelial cells. This compound exhibits pleiotypic effects on rings deprived of endothelium by inducing both a myotonic response, dependent on the activation of Ca2+ influx via a Ni2+-sensitive pathway, and a myolytic effect, possibly dependent on either the depletion of intracellular Ca2+ stores or antagonism of Ca2+ entry via L-type Ca2+ channels. It is a lipophilic, membrane permeable molecule, capable of generating superoxide anion at both sides of the plasmalemma.
References	[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1572887/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03791086	Recruiting	Bronchiectasis Adult	University of Dundee	November 1 2019	--
NCT01302886	Completed	Smoldering Multiple Myeloma	Novartis Pharmaceuticals\|Novartis	May 2011	Phase 2
NCT00741377	Completed	Multiple Myeloma Bone Disease	Novartis Pharmaceuticals\|Novartis	January 2009	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

BHQ ADC Cytotoxin inhibitor

Chemical Structure

Molecular Weight: 222.32